Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Hoyle M"" wg kryterium: Autor


Tytuł :
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Autorzy :
Mujica-Mota R; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Varley-Campbell J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Tikhonova I; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Cooper C; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Griffin E; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Haasova M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Peters J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Lucherini S; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Talens-Bou J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Long L; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Sherriff D; Plymouth Oncology Centre, Plymouth Hospitals NHS Trust, Plymouth, UK.
Napier M; Exeter Oncology Centre, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK.
Ramage J; Neuroendocrine Tumour Service, King's College Hospital NHS Foundation Trust, London, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2018 Sep; Vol. 22 (49), pp. 1-326.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Everolimus/*therapeutic use
Neuroendocrine Tumors/*drug therapy
Octreotide/*analogs & derivatives
Organometallic Compounds/*therapeutic use
Radioisotopes/*therapeutic use
Sunitinib/*therapeutic use
Antineoplastic Agents/adverse effects ; Antineoplastic Agents/economics ; Antineoplastic Combined Chemotherapy Protocols/economics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cost-Benefit Analysis ; Digestive System Neoplasms/drug therapy ; Digestive System Neoplasms/pathology ; Disease Progression ; Everolimus/adverse effects ; Everolimus/economics ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Neoplasm Metastasis ; Neuroendocrine Tumors/pathology ; Octreotide/adverse effects ; Octreotide/economics ; Octreotide/therapeutic use ; Organometallic Compounds/adverse effects ; Organometallic Compounds/economics ; Quality-Adjusted Life Years ; Radioisotopes/adverse effects ; Radioisotopes/economics ; Randomized Controlled Trials as Topic ; Sunitinib/adverse effects ; Sunitinib/economics
Czasopismo naukowe
Tytuł :
EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.
Autorzy :
Dickson R; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK. .
Boland A; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK.
Duarte R; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK.
Kotas E; Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Liverpool, L69 3GB, UK.
Woolacott N; Centre for Reviews and Dissemination, University of York, York, UK.
Hodgson R; Centre for Reviews and Dissemination, University of York, York, UK.
Riemsma R; Kleijnen Systematic Reviews, York, UK.
Grimm S; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.
Ramaekers B; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.
Joore M; Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Center, Maastricht, The Netherlands.
Büyükkaramikli N; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Kaltenthaler E; School of Health and Related Research, The University of Sheffield, Sheffield, UK.
Stevenson M; School of Health and Related Research, The University of Sheffield, Sheffield, UK.
Pandor A; School of Health and Related Research, The University of Sheffield, Sheffield, UK.
Edwards S; BMJ Technology Assessment Group, BMJ, London, UK.
Hoyle M; Peninsula Technology Assessment Group, University of Exeter Medical School, Exeter, UK.
Shepherd J; Southampton Health Technology Assessments Centre, University of Southampton, Southampton, UK.
Armoiry X; Warwick Evidence, University of Warwick, Coventry, UK.
Brazzelli M; Health Services Research Unit, University of Aberdeen, Aberdeen, UK.
Pokaż więcej
Źródło :
Applied health economics and health policy [Appl Health Econ Health Policy] 2018 Aug; Vol. 16 (4), pp. 429-432.
Typ publikacji :
Editorial
MeSH Terms :
Drug Approval*/methods
Drug Approval*/organization & administration
Drug Approval*/statistics & numerical data
Antineoplastic Agents/*therapeutic use
European Union/organization & administration ; Humans ; Uncertainty ; United Kingdom
Opinia redakcyjna
Tytuł :
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
Autorzy :
Tikhonova IA; Peninsula Technology Assessment Group (PenTAG), University of Exeter, South Cloisters 3.09, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK. .
Huxley N; Monash University, Melbourne, VIC, Australia.
Snowsill T; Peninsula Technology Assessment Group (PenTAG), University of Exeter, South Cloisters 3.09, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK.
Crathorne L; Roboleo Ltd, York, UK.
Varley-Campbell J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, South Cloisters 3.09, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK.
Napier M; Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, South Cloisters 3.09, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK.
Pokaż więcej
Źródło :
PharmacoEconomics [Pharmacoeconomics] 2018 Jul; Vol. 36 (7), pp. 837-851.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*economics
Camptothecin/*analogs & derivatives
Cetuximab/*economics
Colonic Neoplasms/*economics
Colorectal Neoplasms/*economics
Cost-Benefit Analysis/*statistics & numerical data
Panitumumab/*economics
Antibodies, Monoclonal, Humanized/economics ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Camptothecin/economics ; Camptothecin/therapeutic use ; Cetuximab/therapeutic use ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/genetics ; Colonic Neoplasms/secondary ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/secondary ; Female ; Fluorouracil/economics ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/economics ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Models, Economic ; Organoplatinum Compounds/economics ; Organoplatinum Compounds/therapeutic use ; Panitumumab/therapeutic use ; Proto-Oncogene Proteins p21(ras)/genetics ; Quality-Adjusted Life Years ; Randomized Controlled Trials as Topic/statistics & numerical data ; Survival Analysis
SCR Protocol :
Folfox protocol; IFL protocol
Czasopismo naukowe
Tytuł :
Arthroscopic Pectoralis Minor Release.
Autorzy :
Hendrix ST; Steadman Hawkins Clinic of the Carolinas, Greenville, South Carolina, U.S.A.
Hoyle M; Hawkins Foundation, Greenville, South Carolina, U.S.A.
Tokish JM; Mayo Clinic Arizona, Scottsdale, Arizona, U.S.A.
Pokaż więcej
Źródło :
Arthroscopy techniques [Arthrosc Tech] 2018 May 07; Vol. 7 (6), pp. e589-e594. Date of Electronic Publication: 2018 May 07 (Print Publication: 2018).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal.
Autorzy :
Tikhonova IA; Peninsula Technology Assessment Group (PenTAG), Exeter, UK. .
Jones-Hughes T; Peninsula Technology Assessment Group (PenTAG), Exeter, UK.
Dunham J; Peninsula Technology Assessment Group (PenTAG), Exeter, UK.
Warren FC; Peninsula Technology Assessment Group (PenTAG), Exeter, UK.
Robinson S; Peninsula Technology Assessment Group (PenTAG), Exeter, UK.
Stephens P; Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), Exeter, UK.
Pokaż więcej
Źródło :
PharmacoEconomics [Pharmacoeconomics] 2018 Apr; Vol. 36 (4), pp. 507.
Typ publikacji :
Journal Article; Published Erratum
Czasopismo naukowe
Tytuł :
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Autorzy :
Huxley N; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Crathorne L; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Varley-Campbell J; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Tikhonova I; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Snowsill T; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Briscoe S; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Peters J; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Bond M; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Napier M; Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2017 Jun; Vol. 21 (38), pp. 1-294.
Typ publikacji :
Journal Article; Review; Systematic Review
MeSH Terms :
Treatment Outcome*
Antibodies, Monoclonal/*administration & dosage
Antibodies, Monoclonal/*economics
Antineoplastic Agents/*administration & dosage
Antineoplastic Agents/*economics
Antineoplastic Agents, Immunological/*administration & dosage
Antineoplastic Agents, Immunological/*economics
Cetuximab/*administration & dosage
Cetuximab/*economics
Colorectal Neoplasms/*drug therapy
Neoplasm Metastasis/*drug therapy
Cost-Benefit Analysis ; Female ; Humans ; Male ; Panitumumab ; Technology Assessment, Biomedical
Czasopismo naukowe
Tytuł :
Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Autorzy :
Jones-Hughes T; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Snowsill T; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Haasova M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Coelho H; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Crathorne L; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Cooper C; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Mujica-Mota R; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Peters J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Varley-Campbell J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Huxley N; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Moore J; Exeter Kidney Unit, Royal Devon and Exeter Foundation Trust Hospital, Exeter, UK.
Allwood M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Lowe J; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Hyde C; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Bond M; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Anderson R; Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2016 Aug; Vol. 20 (62), pp. 1-594.
Typ publikacji :
Journal Article; Review; Systematic Review
MeSH Terms :
Immunosuppressive Agents/*economics
Immunosuppressive Agents/*therapeutic use
Kidney Failure, Chronic/*surgery
Kidney Transplantation/*methods
Abatacept/economics ; Abatacept/therapeutic use ; Antibodies, Monoclonal ; Antilymphocyte Serum ; Basiliximab ; Bayes Theorem ; Cost-Benefit Analysis ; Everolimus/economics ; Everolimus/therapeutic use ; Graft Rejection/prevention & control ; Humans ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/adverse effects ; Models, Economic ; Mycophenolic Acid/economics ; Mycophenolic Acid/therapeutic use ; Quality of Life ; Quality-Adjusted Life Years ; Randomized Controlled Trials as Topic ; Recombinant Fusion Proteins ; Sirolimus/economics ; Sirolimus/therapeutic use ; Tacrolimus/economics ; Tacrolimus/therapeutic use ; Technology Assessment, Biomedical
Czasopismo naukowe
Tytuł :
Exploring the meaning of community for older Australians.
Autorzy :
Hoyle M; School of Health and Rehabilitation Sciences, The University of Queensland, St Lucia, Qld, Australia.
Ryan C; School of Health and Rehabilitation Sciences, The University of Queensland, St Lucia, Qld, Australia.
Gustafsson L; School of Health and Rehabilitation Sciences, The University of Queensland, St Lucia, Qld, Australia.
Pokaż więcej
Źródło :
Australian occupational therapy journal [Aust Occup Ther J] 2016 Apr; Vol. 63 (2), pp. 86-94. Date of Electronic Publication: 2015 Dec 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Environment*
Residence Characteristics*
Social Environment*
Occupational Therapy/*organization & administration
Social Participation/*psychology
Aged ; Aged, 80 and over ; Aging ; Cross-Sectional Studies ; Female ; Health Status ; Humans ; Male ; Qualitative Research ; Queensland ; Social Support ; Socioeconomic Factors
Czasopismo naukowe
Tytuł :
Single-Case-Design Study of Finger-to-Axilla Compression Bandaging for Edema of the Hemiplegic Upper Limb.
Autorzy :
Gustafsson L; Louise Gustafsson, PhD, is Associate Professor, School of Health and Rehabilitation Sciences, The University of Queensland, St. Lucia, Brisbane, Queensland, Australia; .
Lunnon J; Jessica Lunnon was Occupational Therapy Student, School of Health and Rehabilitation Sciences, The University of Queensland, St. Lucia, Brisbane, Queensland, Australia.
Hoyle M; Melanie Hoyle, MOccThySt, is Associate Lecturer, School of Health and Rehabilitation Sciences, The University of Queensland, St. Lucia, Brisbane, Queensland, Australia.
Marshall K; Kathryn Marshall is Occupational Therapist, Department of Occupational Therapy, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Bower K; Kylie Bower is Occupational Therapist, Department of Occupational Therapy, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Pokaż więcej
Źródło :
The American journal of occupational therapy : official publication of the American Occupational Therapy Association [Am J Occup Ther] 2016 Mar-Apr; Vol. 70 (2), pp. 7002210010p1-7.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Compression Bandages*
Stroke Rehabilitation*
Upper Extremity*
Edema/*therapy
Arm ; Axilla ; Edema/etiology ; Hand ; Hemiplegia/complications ; Humans ; Stroke/complications
Czasopismo naukowe
Tytuł :
The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
Autorzy :
Crathorne L; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Huxley N; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Haasova M; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Snowsill T; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Jones-Hughes T; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Hoyle M; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Briscoe S; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Coelho H; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Long L; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Medina-Lara A; University of Exeter Medical School, Exeter, UK.
Mujica-Mota R; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Napier M; Royal Devon and Exeter Hospital, Exeter, UK.
Hyde C; Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK.
Pokaż więcej
Źródło :
Health technology assessment (Winchester, England) [Health Technol Assess] 2016 Feb; Vol. 20 (13), pp. 1-588, v-vi.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review; Systematic Review
MeSH Terms :
Cost-Benefit Analysis*
Technology Assessment, Biomedical*
Anemia/*drug therapy
Hematinics/*therapeutic use
Neoplasms/*drug therapy
Anemia/economics ; Anemia/etiology ; Hematinics/economics ; Humans ; Models, Economic ; Neoplasms/economics ; Quality-Adjusted Life Years
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies